Retraction to: HDAC 1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways (Journal of Pineal Research, (2015), 59, 3, (321-333), 10.1111/jpi.12261);HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways

Journal of Pineal Research

Volumn 59, Issue 3, 2015, Pages 321-333

  Fan, Chongxi ^a   Pan, Yunhu ^b   Yang, Yang ^c   Di, Shouyin ^a   Jiang, Shuai ^c   Ma, Zhiqiang ^a   Li, Tian ^c   Zhang, Zhipei ^a   Li, Weimiao ^a   Li, Xiaofei ^a   Reiter, Russel J ^d   Yan, Xiaolong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Respiratory Medicine   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

histone deacetylase inhibitor; histone deacetylases; human lung adenocarcinoma; melatonin

Indexed keywords

BETA ACTIN; CASPASE 3; GLUTATHIONE; HISTONE DEACETYLASE 1; HISTONE H3; MELATONIN; PROTEIN BAX; PROTEIN BCL 2; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE;

ADENOCARCINOMA CELL LINE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ADENOCARCINOMA; OXIDATIVE STRESS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; LUNG TUMOR; METABOLISM; TUMOR CELL LINE;

ADENOCARCINOMA; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; GLUTATHIONE; HISTONE DEACETYLASE 1; HUMANS; LUNG NEOPLASMS; MELATONIN; OXIDATIVE STRESS;

EID: 84942199946     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12612     Document Type: Erratum

References (61)

1. Torre LA, Bray F, Siegel RL, et al., Global cancer statistics, 2012. Cancer J Clin 2015; 65: 87-108.
2. Ettinger DS, Akerley W, Borghaei H, et al., Non-small cell lung cancer, version 2.2013. J Nat Compr Canc Netw 2013; 11: 645-653; quiz 653.
3. Davidson MR, Gazdar AF, Clarke BE,. The pivotal role of pathology in the management of lung cancer. J Thor Dis 2013; 5 (Suppl 5): S463-S478.
4. Langer CJ, Besse B, Gualberto A, et al., The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 5311-5320.
5. Cao M, Hou D, Liang H, et al., miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer 2014; 50: 1013-1024.
6. Johnson DH, Schiller JH, Bunn PA Jr,. Recent clinical advances in lung cancer management. J Clin Oncol 2014; 32: 973-982.
7. Zhang HM, Zhang Y,. Melatonin: a well-documented antioxidant with conditional pro-oxidant actions. J Pineal Res 2014; 57: 131-146.
8. Hardeland R,. Melatonin and the theories of aging: a critical appraisal of melatonin's role in antiaging mechanisms. J Pineal Res 2013; 55: 325-356.
9. Govender J, Loos B, Marais E, et al., Mitochondrial catastrophe during doxorubicin-induced cardiotoxicity: a review of the protective role of melatonin. J Pineal Res 2014; 57: 367-380.
10. Alvarez-Garcia V, Gonzalez A, Alonso-Gonzalez C, et al., Melatonin interferes in the desmoplastic reaction in breast cancer by regulating cytokine production. J Pineal Res 2012; 52: 282-290.
11. Uguz AC, Cig B, Espino J, et al., Melatonin potentiates chemotherapy-induced cytotoxicity and apoptosis in rat pancreatic tumor cells. J Pineal Res 2012; 53: 91-98.
12. Sanchez-Hidalgo M, Lee M, de la Lastra CA, et al., Melatonin inhibits cell proliferation and induces caspase activation and apoptosis in human malignant lymphoid cell lines. J Pineal Res 2012; 53: 366-173.
13. Plaimee P, Weerapreeyakul N, Thumanu K, et al., Melatonin induces apoptosis through biomolecular changes, in SK-LU-1 human lung adenocarcinoma cells. Cell Prolif 2014; 47: 564-577.
14. Fic M, Podhorska-Okolow M, Dziegiel P, et al., Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo 2007; 21: 513-518.
15. Plaimee P, Weerapreeyakul N, Barusrux S, et al., Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells. Cell Prolif 2015; 48: 67-77.
16. Olsen CA,. Expansion of the lysine acylation landscape. Ang Chemie 2012; 51: 3755-3756.
17. Lane AA, Chabner BA,. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009; 27: 5459-5468.
18. Abend A, Kehat I,. Histone deacetylases as therapeutic targets-from cancer to cardiac disease. Pharmacol Therap 2015; 147: 55-62.
19. Feng W, Zhang B, Cai D, et al., Therapeutic potential of histone deacetylase inhibitors in pancreatic cancer. Cancer Lett 2014; 347: 183-190.
20. Gallinari P, di Marco S, Jones P, et al., HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res 2007; 17: 195-211.
21. Nakagawa M, Oda Y, Eguchi T, et al., Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 2007; 18: 769-774.
22. Lin YC, Lin YC, Shih JY, et al., DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers. Clin Cancer Res 2015; 21: 428-438.
23. Minucci S, Pelicci PG,. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6: 38-51.
24. Peart MJ, Tainton KM, Ruefli AA, et al., Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003; 63: 4460-4471.
25. Spiegel S, Milstien S, Grant S,. Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene 2012; 31: 537-551.
26. Delcuve GP, Khan DH, Davie JR,. Targeting class I histone deacetylases in cancer therapy. Expert Opin Therap Targets 2013; 17: 29-41.
27. Jawed S, Kim B, Ottenhof T, et al., Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 2007; 560: 17-22.
28. Wei JY, Li WM, Zhou LL, et al., Melatonin induces apoptosis of colorectal cancer cells through HDAC4 nuclear import mediated by CaMKII inactivation. J Pineal Res 2015; 58: 429-438.
29. Cheng Y, Cai L, Jiang P, et al., SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. Eur J Pharmacol 2013; 715: 219-229.
30. Kim KW, Hwang M, Moretti L, et al., Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 2008; 4: 659-668.
31. Chiao MT, Cheng WY, Yang YC, et al., Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells. Autophagy 2013; 9: 1509-1526.
32. Ortiz-Lopez L, Morales-Mulia S, Ramirez-Rodriguez G, et al., ROCK-regulated cytoskeletal dynamics participate in the inhibitory effect of melatonin on cancer cell migration. J Pineal Res 2009; 46: 15-21.
33. Zhang S, Yang Y, Liang Z, et al., Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells. PLoS ONE 2013; 8: e83699.
34. Cohen LA, Marks PA, Rifkind RA, et al., Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 2002; 22: 1497-1504.
35. Butler LM, Agus DB, Scher HI, et al., Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-5170.
36. Wang L, Chen G, Chen K, et al., Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach. Oncotarget 2015; 6: 9740-9755.
37. Chou TC, Talalay P,. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22: 27-55.
38. Yun M, Kim EO, Lee D, et al., Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. Cell Physiol Biochem 2014; 34: 865-872.
39. Zhou Q, Gui S, Zhou Q, et al., Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway. PLoS ONE 2014; 9: e101132.
40. Kontek R, Nowicka H,. The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. Drug Chem Toxicol 2013; 36: 335-342.
41. Alonso-Gonzalez C, Gonzalez A, Martinez-Campa C, et al., Melatonin sensitizes human breast cancer cells to ionizing radiation by downregulating proteins involved in double-strand DNA break repair. J Pineal Res 2015; 58: 189-197.
42. Leon J, Casado J, Jimenez RUIZSM, et al., Melatonin reduces endothelin-1 expression and secretion in colon cancer cells through the inactivation of FoxO-1 and NF-kappabeta. J Pineal Res 2014; 56: 415-426.
43. Jung-Hynes B, Schmit TL, Reagan-Shaw SR, et al., Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 2011; 50: 140-149.
44. Neal JW, Sequist LV,. Complex role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. J Clin Oncol 2012; 30: 2280-2282.
45. Weber DM, Graef T, Hussein M, et al., Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319-324.
46. Halkidou K, Gaughan L, Cook S, et al., Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer. Prostate 2004; 59: 177-189.
47. Heideman MR, Wilting RH, Yanover E, et al., Dosage-dependent tumor suppression by histone deacetylases 1 and 2 through regulation of c-Myc collaborating genes and p53 function. Blood 2013; 121: 2038-2050.
48. Santoro F, Botrugno OA, Dal Zuffo R, et al., A dual role for Hdac1: oncosuppressor in tumorigenesis, oncogene in tumor maintenance. Blood 2013; 121: 3459-3468.
49. Dovey OM, Foster CT, Conte N, et al., Histone deacetylase 1 and 2 are essential for normal T-cell development and genomic stability in mice. Blood 2013; 121: 1335-1344.
50. Adams JM, Cory S,. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-1326.
51. Salvesen GS, Dixit VM,. Caspases: intracellular signaling by proteolysis. Cell 1997; 91: 443-446.
52. Antonsson B, Martinou JC,. The Bcl-2 protein family. Exp Cell Res 2000; 256: 50-57.
53. Dar AA, Belkhiri A, Ecsedy J, et al., Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res 2008; 68: 8998-9004.
54. Radogna F, Albertini MC, de Nicola M, et al., Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyeicosatetraenoic acid. Mitochondrion 2015; 21: 113-121.
55. Kim HS, Kim TJ, Yoo YM,. Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells. PLoS ONE 2014; 9: e92627.
56. Stoimenov I, Helleday T,. PCNA on the crossroad of cancer. Biochem Soc Transact 2009; 37: 605-613.
57. Punchihewa C, Inoue A, Hishiki A, et al., Identification of small molecule proliferating cell nuclear antigen (PCNA) inhibitor that disrupts interactions with PIP-box proteins and inhibits DNA replication. J Biol Chem 2012; 287: 14289-14300.
58. Xi SC, Siu SW, Fong SW, et al., Inhibition of androgen-sensitive LNCaP prostate cancer growth in vivo by melatonin: association of antiproliferative action of the pineal hormone with mt1 receptor protein expression. Prostate 2001; 46: 52-61.
59. Dasmahapatra G, Patel H, Nguyen T, et al., PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or-resistant BCR/ABL+ leukemia cells in vitro and in vivo. Clinical Cancer Res 2013; 19: 404-414.
60. You BR, Kim SH, Park WH,. Reactive oxygen species, glutathione, and thioredoxin influence suberoyl bishydroxamic acid-induced apoptosis in A549 lung cancer cells. Tumour Biol 2015; 36: 3429-3439.
61. Shin EJ, Chung YH, Le HL, et al., Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int J Neuropsychopharmacol 2015; 18: [Epub ahead of print].